JP2019511556A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511556A5 JP2019511556A5 JP2018554375A JP2018554375A JP2019511556A5 JP 2019511556 A5 JP2019511556 A5 JP 2019511556A5 JP 2018554375 A JP2018554375 A JP 2018554375A JP 2018554375 A JP2018554375 A JP 2018554375A JP 2019511556 A5 JP2019511556 A5 JP 2019511556A5
- Authority
- JP
- Japan
- Prior art keywords
- lactose
- preparation according
- inhalation
- inhalation preparation
- particle size
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 11
- 239000008101 lactose Substances 0.000 claims 11
- OJIXTCWHYBRFHL-LEEOIRFPSA-L magnesium (2S,3S,4S,5R,6R)-6-[(2S,3R,4S,5S,6S)-2-[[(3S,4aR,6aR,6bS,8aS,11S,12aS,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]-6-carboxylato-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical group [Mg++].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O OJIXTCWHYBRFHL-LEEOIRFPSA-L 0.000 claims 9
- 239000002245 particle Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 4
- 239000006199 nebulizer Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010019799 Hepatitis viral Diseases 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000003002 pH adjusting agent Substances 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 238000007873 sieving Methods 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 201000001862 viral hepatitis Diseases 0.000 claims 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 235000011054 acetic acid Nutrition 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 235000011114 ammonium hydroxide Nutrition 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 230000003419 expectorant effect Effects 0.000 claims 1
- 239000010419 fine particle Substances 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 235000001727 glucose Nutrition 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 235000011167 hydrochloric acid Nutrition 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000007951 isotonicity adjuster Substances 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 150000003904 phospholipids Chemical group 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 238000011450 sequencing therapy Methods 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 235000017550 sodium carbonate Nutrition 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 235000011083 sodium citrates Nutrition 0.000 claims 1
- 235000011121 sodium hydroxide Nutrition 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000008215 water for injection Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021126412A JP7309791B2 (ja) | 2016-04-15 | 2021-08-02 | イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610237175 | 2016-04-15 | ||
| CN201610237175.3 | 2016-04-15 | ||
| PCT/CN2017/080583 WO2017177966A1 (zh) | 2016-04-15 | 2017-04-14 | 异甘草酸或其盐的吸入制剂及其在制备治疗呼吸系统疾病药物中的应用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021126412A Division JP7309791B2 (ja) | 2016-04-15 | 2021-08-02 | イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2019511556A JP2019511556A (ja) | 2019-04-25 |
| JP2019511556A5 true JP2019511556A5 (enExample) | 2020-05-21 |
| JPWO2017177966A5 JPWO2017177966A5 (enExample) | 2022-06-23 |
| JP7166929B2 JP7166929B2 (ja) | 2022-11-08 |
Family
ID=60042326
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554375A Active JP7166929B2 (ja) | 2016-04-15 | 2017-04-14 | イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの使用 |
| JP2021126412A Active JP7309791B2 (ja) | 2016-04-15 | 2021-08-02 | イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021126412A Active JP7309791B2 (ja) | 2016-04-15 | 2021-08-02 | イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20190117568A1 (enExample) |
| EP (1) | EP3443954A4 (enExample) |
| JP (2) | JP7166929B2 (enExample) |
| KR (1) | KR102410183B1 (enExample) |
| CN (2) | CN111920785B (enExample) |
| AU (1) | AU2017251548B2 (enExample) |
| BR (1) | BR112018071208A2 (enExample) |
| EA (1) | EA201892350A1 (enExample) |
| MX (1) | MX394106B (enExample) |
| MY (1) | MY204600A (enExample) |
| PH (1) | PH12018502195A1 (enExample) |
| SG (2) | SG11201809042SA (enExample) |
| WO (1) | WO2017177966A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119345161A (zh) * | 2024-12-25 | 2025-01-24 | 江苏长泰药业股份有限公司 | 一种丙酮酸钠雾化吸入制剂及其制备方法和应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4891221A (en) * | 1988-11-23 | 1990-01-02 | Edward Shanborm | Whole blood antiviral process and composition |
| WO2005004913A1 (ja) * | 2003-07-09 | 2005-01-20 | Anges Mg, Inc. | デコイを含む薬学的組成物およびその使用方法 |
| JP2009513529A (ja) * | 2003-07-11 | 2009-04-02 | グラクソ グループ リミテッド | ステアリン酸マグネシウムを含む医薬製剤 |
| CN101023953B (zh) * | 2006-07-24 | 2010-05-12 | 南开大学 | 治疗支气管哮喘的组合物 |
| CN101190232B (zh) * | 2006-11-30 | 2011-08-17 | 江苏正大天晴药业股份有限公司 | 一种注射用异甘草酸镁冻干粉针剂及其制备方法 |
| JP2008222682A (ja) * | 2007-03-15 | 2008-09-25 | Kumamoto Univ | 線維化肺疾患治療薬、気道粘液分泌細胞過形成抑制剤および気道塞栓治療薬 |
| CN101396368B (zh) * | 2007-09-29 | 2010-12-01 | 江苏正大天晴药业股份有限公司 | 异甘草酸或其盐在制备治疗过敏性鼻炎药物中的应用 |
| CN101669962A (zh) * | 2009-09-18 | 2010-03-17 | 杭州市第六人民医院 | 复合甘草酸氨基酸注射液及其制备方法和应用 |
| CA2809031C (en) * | 2010-08-25 | 2018-10-16 | Weijian Zhang | Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis |
| CN103156930A (zh) * | 2011-12-19 | 2013-06-19 | 张亚军 | 一种含芍药和甘草提取物的呼吸道给药制剂 |
| SG11201404522VA (en) | 2012-03-13 | 2014-10-30 | Respivert Ltd | Crystalline pi3 kinase inhibitors |
| CN102920936A (zh) * | 2012-09-17 | 2013-02-13 | 陈泉生 | 一种治疗呼吸道疾病的吸盐物及其制作方法 |
| CN104042573A (zh) * | 2014-06-03 | 2014-09-17 | 青岛市市立医院 | 一种异甘草酸镁冻干粉针剂及其制备方法 |
| CN106237297A (zh) * | 2016-08-30 | 2016-12-21 | 吉林紫鑫药业股份有限公司 | 一种用于治疗慢性支气管炎的药物组合物 |
-
2017
- 2017-04-14 SG SG11201809042SA patent/SG11201809042SA/en unknown
- 2017-04-14 EP EP17781942.2A patent/EP3443954A4/en active Pending
- 2017-04-14 BR BR112018071208-6A patent/BR112018071208A2/pt not_active Application Discontinuation
- 2017-04-14 CN CN202010842414.4A patent/CN111920785B/zh active Active
- 2017-04-14 EA EA201892350A patent/EA201892350A1/ru unknown
- 2017-04-14 AU AU2017251548A patent/AU2017251548B2/en active Active
- 2017-04-14 CN CN201780018629.0A patent/CN109069442B/zh active Active
- 2017-04-14 SG SG10202010192YA patent/SG10202010192YA/en unknown
- 2017-04-14 MX MX2018012461A patent/MX394106B/es unknown
- 2017-04-14 JP JP2018554375A patent/JP7166929B2/ja active Active
- 2017-04-14 MY MYPI2018703789A patent/MY204600A/en unknown
- 2017-04-14 WO PCT/CN2017/080583 patent/WO2017177966A1/zh not_active Ceased
- 2017-04-14 KR KR1020187033045A patent/KR102410183B1/ko active Active
- 2017-04-14 US US16/093,087 patent/US20190117568A1/en not_active Abandoned
-
2018
- 2018-10-12 PH PH12018502195A patent/PH12018502195A1/en unknown
-
2020
- 2020-08-07 US US16/988,289 patent/US11534398B2/en active Active
-
2021
- 2021-08-02 JP JP2021126412A patent/JP7309791B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019031514A5 (enExample) | ||
| HRP20220919T3 (hr) | Sastav za inhalaciju koji sadrži aklidinij za liječenje kronične opstruktivne bolesti pluća | |
| NZ585856A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| NZ515596A (en) | Medicament compositions, based on anticholinergically effective compounds and beta-mimetics | |
| BR112013009153B1 (pt) | Composição farmacêutica e uso da mesma | |
| Hassoun et al. | Formulating powder–device combinations for salmeterol xinafoate dry powder inhalers | |
| TW202241457A (zh) | 用於預防病毒及微生物感染及其等之後遺症之藥物、治療組合、及方法 | |
| RU2008124825A (ru) | Органические соединения, включающие соль гликопиррония | |
| US20230158259A1 (en) | Products of manufacture and methods for treating, ameliorating or preventing microbial infections | |
| WO2013104892A1 (en) | Application of high dose compounds via inhalation | |
| BR102012026195A2 (pt) | Método de produção de um medicamento de nicotina e um medicamento feito pelo método | |
| CN116635018A (zh) | 吸入用药物组合物 | |
| JPH0892098A (ja) | 肺結核治療剤 | |
| CN111818912A (zh) | 用于通过肺部给药而治疗抑郁症的干粉氯胺酮组合物 | |
| US12005049B2 (en) | Methods of preventing cancer metastasis | |
| JP2019511556A5 (enExample) | ||
| US20130291860A1 (en) | Method For Treating Cystic Fibrosis with Inhaled Denufosol | |
| JP2025122121A (ja) | 肺線維症を処置するための方法及び組成物 | |
| JPH11106339A (ja) | Ｃｒ２０３９を含有する吸入用医薬組成物 | |
| JP2013241451A (ja) | 生理活性物質含有粒子の製造方法 | |
| TWI762449B (zh) | 噴霧器用組成物 | |
| JP2022502429A (ja) | 肺投与によるうつ病の処置方法における使用のためのケタミン組成物 | |
| RU2633085C2 (ru) | Противовирусное лекарственное средство в виде капсул и способ его получения | |
| US20250213469A1 (en) | Dosage forms of active substances used against viral diseases in dry powder inhaler device for symptoms caused by covid-19 and other viral lung diseases | |
| Buttini et al. | Formulation strategies for antitubercular drugs by inhalation |